Yoshikawa T, Rae V, Bruins-Slot W, Van den Berg J W, Taylor J R, Streilein J W
Department of Microbiology and Immunology, University of Miami School of Medicine, Florida 33101.
J Invest Dermatol. 1990 Nov;95(5):530-6. doi: 10.1111/1523-1747.ep12504877.
Normal, healthy human volunteers and patients with proved history of non-melanoma skin cancer have been tested for their capacity to develop contact hypersensitivity to dinitrochlorobenzene (DNCB) following exposure of buttock skin to acute, low-dose ultraviolet B (UVB) radiation. Using a radiation protocol that achieves virtually complete depletion of normal-appearing Langerhans cells from irradiated skin, it was learned that approximately 60% of healthy volunteers developed vigorous contact hypersensitivity (CH) when 2000 micrograms DNCB was painted on the irradiated site. These individuals were designated UVB-resistant, and were distinguished from other individuals, designated UVB-susceptible, who failed to develop contact hypersensitivity following an identical treatment protocol. It was then discovered that virtually all (92%) skin cancer patients exposed to UVB and DNCB failed to develop CH, i.e., were UVB-susceptible. In subsequent experiments, epicutaneous application of 2000 micrograms DNCB to unirradiated skin of UVB-susceptible individuals revealed a further distinction between normal persons and skin cancer patients. Approximately 45% of the latter (and none of the former) remained unresponsive (failed to develop contact hypersensitivity following this second attempt at sensitization), implying that they had been rendered immunologically tolerant. These tolerant individuals responded normally to the unrelated hapten, diphencyprone. We conclude that human beings resemble inbred strains of laboratory mice in that some individuals are UVB-susceptible, whereas others are UVB-resistant. Because the incidence of UVB-susceptibility was significantly higher in skin cancer patients, and as specific unresponsiveness could be demonstrated only in these patients, we propose that UVB-susceptibility, as we define it in this hapten system, may be a risk factor for the development of skin cancer.
正常、健康的人类志愿者以及有确诊非黑色素瘤皮肤癌病史的患者,在其臀部皮肤暴露于急性、低剂量紫外线B(UVB)辐射后,接受了对二硝基氯苯(DNCB)产生接触性超敏反应能力的测试。采用一种能使受辐照皮肤中外观正常的朗格汉斯细胞几乎完全耗尽的辐射方案,结果发现,当在辐照部位涂抹2000微克DNCB时,约60%的健康志愿者产生了强烈的接触性超敏反应(CH)。这些个体被指定为UVB抗性,与其他个体(指定为UVB易感性)区分开来,后者在相同的治疗方案后未能产生接触性超敏反应。随后发现,几乎所有(92%)暴露于UVB和DNCB的皮肤癌患者都未能产生CH,即属于UVB易感性。在后续实验中,对UVB易感性个体未受辐照的皮肤经皮涂抹2000微克DNCB,揭示了正常人与皮肤癌患者之间的进一步差异。后者中约45%(前者无一例)仍无反应(在第二次致敏尝试后未能产生接触性超敏反应),这意味着他们已产生免疫耐受。这些耐受个体对无关的半抗原二苯环丙烯酮反应正常。我们得出结论,人类与实验室小鼠的近交系相似,即一些个体对UVB敏感,而另一些个体对UVB有抗性。由于皮肤癌患者中UVB敏感性的发生率显著更高,且只有在这些患者中才能证明特异性无反应性,我们提出,在这个半抗原系统中我们所定义的UVB敏感性可能是皮肤癌发生的一个风险因素。